ASPIRE Obstetric Anesthesia Subcommittee Meeting
November 3, 2021
Agenda
• Announcements
• August 2021 Meeting recap
• Glucose Measure Discussion
• Unblinded data review
• PONV measures (if time allows)
Announcements
• 2022 Meeting Dates
– February 2nd, 1pm EST
– August 3rd, 1pm EST
– December 7th, 1pm EST
• GA 02-OB and TEMP 05-OB released
to the dashboards
August Meeting Recap
• BP 04 filtering by neuraxial anesthesia type is available through the “Measure Case Report
Tool”. Please reach out to the coordinating center if you do not have access to this tool and
would like access or if you have any questions about how to download the reports
• Subcommittee confirmed interest in a review of unblinded institutional data at a future
meeting
• Please continue to share your practices around standardization of documentation for
reason to convert to general anesthesia for cesarean delivery cases
• Provider attribution for GA 01 was discussed - consensus to continue without attribution
• For TEMP 05 (hypothermia at the end of the case or in PACU), cases will be flagged if there
are not temperatures taken during that time frame per the recommendation of the
subcommittee
Recap of Perioperative Glucose Measures
Preop Time Period Intraop Time Period PACU Time Period
GLU 02
GLU 03
GLU 04
GLU 05
GLU 01
>200 treated or rechecked in 90 minutes
<60 treated or rechecked in 90 minutes
>200 treated or rechecked in 90 minutes
<60 treated or rechecked in 90 minutes
>200 treated in 90 minutes
Is Glucose Management a key focus area for OB anesthesia?
Conversion
Cases
Labor Epidural Case Cesarean Delivery Case
Preop Time Period Intraop Time Period PACU Time Period
Should GLU 03/04/05 Start here?
Other Cases
Preop Holding OR Case
Preop Time Period Intraop Time Period PACU Time Period
Other cases start GLU 03/04/05 at
“Preop Start”
PACU Recovery
PACU Recovery
• If yes, we can modify GLU 03/04/05 to start at cesarean delivery start OR create separate OB
glucose management measure(s)
• If no, should all cesarean delivery cases be excluded from the existing glucose measures for now?
• Note: labor epidural cases are excluded from the glucose measures
Unblinded Data Review
Reminders
• Per the terms and conditions outlined during the registration process:
– A culture of openness and trust are critical to the development of such a collaborative effort to
improve quality; and a commitment for confidentiality is required to further the goals of ASPIRE.
– The following examples are to be considered privileged and confidential information and should be
discussed only within the confines of the OB Subcommittee Meeting.
– Any and all patient information.
– Any and all patient identifiers/information which are considered privileged and protected
health information as defined by current HIPAA laws.
– Any specific MPOG QI registry case information.
– Any information discussed regarding a specific site outcome.
– Any reference to a specific MPOG site result or analysis.
– All anesthesiology data presented including but not limited to outcome reports.
– Taking screenshots, pictures or videos of data slides is prohibited.
Site Participation
• All sites that perform cesarean deliveries are presented on the slides to follow
• Only those sites with OB Subcommittee membership are unblinded
• Quality and OB Champions were notified that unblinded data would be shared and
were given the opportunity to opt out
• No sites emailed us to express a desire to be excluded from this review
Unblinded Data Review Session: GA 01 and GA 02
Data was removed from the posted slide deck for confidentiality reasons. Please see the posted minutes for
summary of topics discussed.
